New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders
Following the discovery of the endocannabinoid system and its potential as a therapeutic target for various pathological conditions, growing interest led researchers to investigate the role of cannabis and its derivatives for medical purposes. The compounds Δ9-tetrahydrocannabinol and cann...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-10-01
|
| Series: | Medicines |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2305-6320/5/4/107 |
| _version_ | 1829112881050812416 |
|---|---|
| author | Maria Scherma Paolo Masia Matteo Deidda Walter Fratta Gianluigi Tanda Paola Fadda |
| author_facet | Maria Scherma Paolo Masia Matteo Deidda Walter Fratta Gianluigi Tanda Paola Fadda |
| author_sort | Maria Scherma |
| collection | DOAJ |
| description | Following the discovery of the endocannabinoid system and its potential as a therapeutic target for various pathological conditions, growing interest led researchers to investigate the role of cannabis and its derivatives for medical purposes. The compounds Δ9-tetrahydrocannabinol and cannabidiol are the most abundant phytocannabinoids found in cannabis extracts, as well as the most studied. The present review aims to provide an overview of the current evidence for their beneficial effects in treating psychiatric disorders, including schizophrenia, anxiety, and depression. Nevertheless, further investigations are required to clarify many pending issues, especially those relative to the assessment of benefits and risks when using cannabis for therapeutic purposes, thereby also helping national and federal jurisdictions to remain updated. |
| first_indexed | 2024-12-12T15:24:56Z |
| format | Article |
| id | doaj.art-0a1216d7785d42e5af545fa9ea32d02c |
| institution | Directory Open Access Journal |
| issn | 2305-6320 |
| language | English |
| last_indexed | 2024-12-12T15:24:56Z |
| publishDate | 2018-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicines |
| spelling | doaj.art-0a1216d7785d42e5af545fa9ea32d02c2022-12-22T00:20:16ZengMDPI AGMedicines2305-63202018-10-015410710.3390/medicines5040107medicines5040107New Perspectives on the Use of Cannabis in the Treatment of Psychiatric DisordersMaria Scherma0Paolo Masia1Matteo Deidda2Walter Fratta3Gianluigi Tanda4Paola Fadda5Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, ItalyDepartment of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, ItalyDepartment of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, ItalyDepartment of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, ItalyMedication Development program, NIDA-IRP, NIH/DHHS, NIDA suite 3301, Baltimore, MD 21224, USADepartment of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, ItalyFollowing the discovery of the endocannabinoid system and its potential as a therapeutic target for various pathological conditions, growing interest led researchers to investigate the role of cannabis and its derivatives for medical purposes. The compounds Δ9-tetrahydrocannabinol and cannabidiol are the most abundant phytocannabinoids found in cannabis extracts, as well as the most studied. The present review aims to provide an overview of the current evidence for their beneficial effects in treating psychiatric disorders, including schizophrenia, anxiety, and depression. Nevertheless, further investigations are required to clarify many pending issues, especially those relative to the assessment of benefits and risks when using cannabis for therapeutic purposes, thereby also helping national and federal jurisdictions to remain updated.http://www.mdpi.com/2305-6320/5/4/107phytocannabinoidsΔ9-tetrahydrocannabinolcannabidiolpsychiatric disorders |
| spellingShingle | Maria Scherma Paolo Masia Matteo Deidda Walter Fratta Gianluigi Tanda Paola Fadda New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders Medicines phytocannabinoids Δ9-tetrahydrocannabinol cannabidiol psychiatric disorders |
| title | New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders |
| title_full | New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders |
| title_fullStr | New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders |
| title_full_unstemmed | New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders |
| title_short | New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders |
| title_sort | new perspectives on the use of cannabis in the treatment of psychiatric disorders |
| topic | phytocannabinoids Δ9-tetrahydrocannabinol cannabidiol psychiatric disorders |
| url | http://www.mdpi.com/2305-6320/5/4/107 |
| work_keys_str_mv | AT mariascherma newperspectivesontheuseofcannabisinthetreatmentofpsychiatricdisorders AT paolomasia newperspectivesontheuseofcannabisinthetreatmentofpsychiatricdisorders AT matteodeidda newperspectivesontheuseofcannabisinthetreatmentofpsychiatricdisorders AT walterfratta newperspectivesontheuseofcannabisinthetreatmentofpsychiatricdisorders AT gianluigitanda newperspectivesontheuseofcannabisinthetreatmentofpsychiatricdisorders AT paolafadda newperspectivesontheuseofcannabisinthetreatmentofpsychiatricdisorders |